Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01516593
Other study ID # CARMEN
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 2011
Est. completion date August 2015

Study information

Verified date August 2022
Source IRCCS San Raffaele
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter,open-label trial to evaluate activity and safety of the investigational intensive in HIV+ patients with Burkitt's lymphoma. Experimental treatment consists of an induction phase followed by a consolidation or intensified phase according to tumor response. Until recently, the immuno-compromised state of patients with concomitant HIV/AIDS and BL was thought to limit the ability to administer intensive chemotherapeutic regimens due to infection rate. However, the advent of highly active antiretroviral therapy (HAART) and evidence in diffuse large B-cell lymphomas that HIV-positive patients can tolerate standard chemotherapeutic regimens with improved outcomes have led investigators to treat HIV-positive patients with the same intensive chemotherapy regimens used to treat immuno-competent patients. Data suggest that these current approaches, along with supportive care, may result in improved patient outcomes, similar to those in the immuno-competent patient population.


Description:

The activity of feasibility of the proposed program will be assessed in HIV+ patients with Burkitt lymphoma with the aim to improve tolerability, minimize source consuming and supporting treatment and redu ce late sequels. Available combinations in this setting are really source demanding and toxic combinations showing high rates of septic complication and a treatment-related mortality of near 20%.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date August 2015
Est. primary completion date April 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Histologic diagnosis of Burkitt's lymphoma (WHO 2008) - HIV sero-positivity - Age =18 and =60 years - ECOG-PS =3 Exclusion Criteria: - CNS parenchymal involvement - Absolute neutrophil count <1.000 cells/µL and platelets count <75 × 109/L (Burkitt unrelated) - Creatinine >1,5N (Burkitt unrelated) - SGOT and/or SGTP >2,5N (Burkitt unrelated) - Bilirubin >2N (Burkitt unrelated) - Severe psychiatric illness or any other clinical, social or psychological condition that could interfere with patient's adherence and compliance - Significant cardiac disease or acute myocardial infarction in the last 12 months - Severe active infection (except for HBV and/or HCV co-infection)

Study Design


Intervention

Drug:
Induction Phase
dd -2 to 1: Methylprednisolone dd 0-1, Cyclophosphamide, associated on day 0 with Vincristine dd 2, Rituximab dd 7, Methotrexate dd 14, Rituximab dd 15, Etoposide dd 21, Methotrexate dd 29, Rituximab and Doxorubicin dd 36, Rituximab and VCR At the end of this induction phase, subsequent treatment will be performed according to the objective response: pts in CR: consolidation phase followed by bulky site irradiation pts in PR: consolidation phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation pts with SD after induction or PD during or after induction: intensification phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation
Consolidation Phase (on day +50)
dd 1-2: cytarabine twice a day dd 3 and 11: rituximab dd 11-13: leukapheresis for PBPC collection.
Intensification phase
One or two courses of R-IVAC or R-ICE chemoimmunotherapy regimen, every three weeks as debulking. CTX (dd 1) associated with rituximab on dd 3 and 10, followed by PBPC collection (dd 11-13); AraC every 12 hours for four days (dd -5 to -2) supported by reinfusion of CD34+ cells (dd 0), rituximab infusion (dd -1 and +11) and second in-vivo purged PBPC collection (if needed).
BEAM conditioning
BCNU on dd 1; VP-16 every 12 hours on dd 2-5 and araC every 12 hours on dd 2-5; melphalan on dd 6, followed by the reinfusion of CD34+ cells
Radiation:
Consolidation radiotherapy
At the end of the whole program, patients will be evaluated for involved-field irradiation with 6-10 MeV photons and a dose of 36 Gy (2 Gy/d, five fractions a week). Three subgroups of patients will be considered for radiotherapy

Locations

Country Name City State
Italy Oncologia Medica A - Centro di Riferimento Oncologico Aviano (PN)
Italy Ematologia - A.O. Spedali Civili Brescia
Italy Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte Tabor Milano
Italy S.C. Oncologia Medica - Ospedale San Paolo Milano
Italy S.C. Oncologia Medica 3 - IRCCS Istituto Nazionale Tumori (INT) Milano
Italy U.O.C. Immunodeficienze virali - I.N.M.I. L. Spallanzani Roma
Italy S.C. Oncoematologia - A.O. Santa Maria Terni
Italy U.O. Ematologia 2 - Ospedale San Giovanni Battista Torino

Sponsors (1)

Lead Sponsor Collaborator
Andres J. M. Ferreri

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary evaluation of activity of the induction phase in terms of complete remission rate Objective lymphoma response achieved after the induction phase of the experimental treatment. at the end of the induction phase of the investigational intensive chemotherapy, an expected average of 45 days
Secondary Feasibility and tolerability of the investigational intensive chemotherapy in terms of grade =4 adverse events Assessment of incidence of grade 4 AE during experimental treatment (induction, consolidation and intensification phases as well as conditioning and autologous stem cell transplantation (if indicated) participants will be followed for the duration of the whole experimental program, an expected average of 100 days
Secondary Feasibility and tolerability of the consolidation phase followed by BEAM conditioning and autologous stem cell transplantation in terms of prevalence of grade =4 adverse events participants will be followed for the duration of the whole experimental program, an expected average of 100 days
Secondary Feasibility and tolerability of intensification phase in terms of prevalence of grade =4 adverse events Participants who will not achieve a complete or partial response after induction and consolidation phases will be referred to intensification phase, which will be followed by BEAM + ASCT. These patients will be assess for tolerabbility and AE during these therapeutic phases. participants will be followed for the duration of the whole experimental program, an expected average of 100 days
Secondary Activity of the whole investigational program in terms of complete remission rate Participants will be assessed by conventional exams to define complete remission rate after the whole experiemntal program; that is after consolidation phase for patients who achieved complete remission after induction phase, after BEAM + ASCt for patients who achieved partial response after induction phase, and after intensification phase for patients who did not achieve an objective response after induction phase. at the end of the whole program, an expected average of 100 days
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Active, not recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2